At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
In Brief
A Phase 2 clinical trial evaluating Mirabegron and Placebo for Lower Urinary Tract Symptoms and Bladder Outlet Obstruction. Completed, enrolled 200 participants across 27 sites in 2 countries.
Detailed Summary
This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionAug 2008
TodayJul 2026
First PostedDec 13, 2006
Enrollment StartDec 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.6 years ago
Interventions
Mirabegrondrug
oral
Placebodrug
oral